Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.61 |
| ▸ | RAB9A | P51151 | 11/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.59 |
| ▸ | QPCT | Q16769 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 2/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19497780 | 0.98 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| SCHEMBL22039979 | 0.98 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| SCHEMBL17570161 | 0.98 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| SCHEMBL22040024 | 0.98 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| SCHEMBL17933751 | 0.95 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| SCHEMBL1664350 | 0.89 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| Hydrochloric Acid SCHEMBL2124383 | 0.87 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| Hydrochloric Acid SCHEMBL7109842 | 0.86 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 | |
| SCHEMBL11573436 | 0.85 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22039978 | 0.84 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2QPCTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0039835-B1 | PROCESS FOR THE PREPARATION OF 2-AMINO-6-NITRO-BENZOTHIAZOLE | BAYER AG (DE) | 1983-03-09 | — | — | EP | claimed |
| US-10927087-B2 | Method for producing polymerizable compound | DIC CORPORATION (JP) | 2021-02-23 | — | — | US | disclosed |
| US-20200165215-A1 | METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE | DIC CORPORATION (JP) | 2020-05-28 | — | — | US | disclosed |
| CN-104780764-A | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress | BAYER CROPSCIENCE AG | 2015-07-15 | — | — | CN | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-2001511-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1940408-A1 | ADENOSINE A2a RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS | SCHERING CORPORATION (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7338956-B2 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-04 | — | — | US | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
| EP-1638556-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| EP-1534275-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005000301-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014369-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388341-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
| US-6197969-B1 | REACTING METAL SALT OF 2-AMINOTHIOPHENOL WITH AN AMINO ACID-N-CARBOXYLIC ANHYDRIDE; CYCLIZATION IN ACID | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| US-4369324-A | Process for the preparation of 2-amino-6-nitrobenzothiazole | BAYER AKTIENGESELLSCHAFT (DE) | 1983-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | LDLR, LRP6, PLPBP | NPC1 1840/4885RAB9A 3129/4885SMN1; SMN2 4531/4885 |
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | EDNRA, LIPG, CYP11B1 | NPC1 1665/4885RAB9A 3101/4885SMN1; SMN2 4704/4885 |
| US-20200165215-A1 | METHOD FOR PRODUCING 2-HYDRAZINOBENZOTHIAZOLE DERIVATIVE | HAO2, IDH2, HACL2 | NPC1 2261/4885RAB9A 3845/4885SMN1; SMN2 4509/4885 |
| US-10927087-B2 | Method for producing polymerizable compound | INCENP, INF2, INHA | NPC1 4131/4885RAB9A 3222/4885SMN1; SMN2 2311/4885 |
| US-20040266845-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | NPC1 237/4885RAB9A 900/4885SMN1; SMN2 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.